VIP
clinical trialsAlso known as: Vasoactive Intestinal Peptide, Aviptadil
**Mechanism of Action** Vasoactive Intestinal Peptide (VIP; 28 amino acids) exerts its effects primarily through G-protein-coupled VPAC1 and VPAC2 receptors, which are widely expressed in the respiratory, cardiovascular, gastrointestinal, and immune systems. Activation of these receptors stimulates adenylate cyclase, increasing intracellular cAMP, leading to smooth muscle relaxation (vasodilation, bronchodilation), inhibition of pro-inflammatory cytokine release, and modulation of T-cell responses. VIP also suppresses NF-κB signaling and promotes regulatory T-cell differentiation, contributing to its anti-inflammatory profile. **Key Research Findings** Clinical trials have investigated synthetic VIP (aviptadil) for acute respiratory distress syndrome (ARDS), pulmonary hypertension, and inflammatory bowel disease. In phase II/III trials for COVID-19-related ARDS, intravenous aviptadil improved oxygenation and reduced mortality in severe cases, though results varied by subgroup. Preclinical studies demonstrate VIP’s neuroprotective effects in models of Parkinson’s and Alzheimer’s disease, mediated by reduced microglial activation and enhanced neuronal survival. Pharmacokinetic challenges (short half-life, ~2–3 minutes) have driven development of sustained-release formulations and analogs. **Clinical Relevance** VIP is approved in some regions for erectile dysfunction (intracavernosal) and pulmonary hypertension (inhalation). Ongoing trials target sarcoidosis, pulmonary fibrosis, and autoimmune uveitis. Its dual vasodilatory and anti-inflammatory actions position it as a candidate for conditions involving ischemia-reperfusion injury and chronic inflammation. However, rapid degradation and systemic side effects (hypotension, flushing) limit widespread use. For research purposes only — not medical advice.
Key data
C147H237N43O43SResearch & studies
VIP is an abundant neurotransmitter in the lungs with diverse biological impacts.; VIP is involved in multiple pulmonary diseases such as asthma, cystic fibrosis, and lung tumors.; Two main limitations of VIP as a medication are outlined.; Extended-release formulations and VIP analogues are being developed to address these limitations.
On-VIP and On-VIPR1 genes were identified in Nile tilapia, with high expression in the intestine and induction by S. agalatiae.; On-VIP reduced expression of P65, P38, MyD88, STAT3, and AP1 while upregulating CREB and CBP.; In vivo, On-VIP protected tilapia from bacterial infection and promoted apoptosis and pyroptosis.
VIP stimulates glucose-dependent insulin secretion primarily via VPAC2 receptors.; VIP promotes islet β-cell proliferation through the forkhead box M1 pathway.; Clinical application of VIP is limited due to its short half-life and wide distribution.; VPAC2-selective agonists are being developed as potential novel hypoglycemic drugs.
Sympathectomy impaired femoral micro-architecture, bone density, and mechanical properties.; VIP expression at the fracture site was significantly decreased in sympathectomized mice.; VIP treatment rescued the repressive effects of sympathectomy on bone remodeling and increased osteogenic markers OCN and OPN.; VIP promoted fracture healing by inhibiting bone resorption.
VIP-INs are emerging as important regulators of network dynamics and normal circuit development.; VIP-IN dysfunction is implicated in models of genetically determined neurodevelopmental disorders.; Recurring VIP-IN-mediated circuit motifs are shared across cerebral cortical areas.; Underexplored disease-associated genes highly expressed in VIP-INs are linked to autism spectrum disorder and intellectual disability.
Frequently asked questions
What is VIP?
**Mechanism of Action** Vasoactive Intestinal Peptide (VIP; 28 amino acids) exerts its effects primarily through G-protein-coupled VPAC1 and VPAC2 receptors, which are widely expressed in the respiratory, cardiovascular, gastrointestinal, and immune systems. Activation of these receptors stimulates adenylate cyclase, i
How does VIP work?
28-aa neuropeptide acting on VPAC1/2 receptors; vasodilatory, bronchodilatory, and anti-inflammatory.
What is the research status of VIP?
VIP is currently classified as clinical trials, with 27,403 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of VIP?
VIP has a molecular weight of approximately 3326.8 g/mol (formula C147H237N43O43S).
Related peptides
38-aa neuropeptide of the VIP/secretin family acting on PAC1 receptors; neuroprotective and vasoregulatory.
43-aa actin-sequestering peptide that drives cell migration, angiogenesis, and repair in cardiac, corneal, and dermal tissue.
Gastric-juice-derived pentadecapeptide that promotes angiogenesis (VEGF) and tissue repair via FAK-paxillin and NO-system modulation.
C-terminal tripeptide of α-MSH with anti-inflammatory action via PepT1 uptake and NF-κB inhibition, studied in IBD models.
Copper-binding tripeptide that stimulates collagen synthesis, wound healing, and remodeling gene expression.
Erythropoietin-derived 11-aa peptide targeting the innate repair receptor (EPOR/CD131) for tissue protection without erythropoiesis.
Build on VIP data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key